BioMed Realty Announces 93,000 Square Foot Lease Expansion And Extension With Ironwood Pharmaceuticals At 301 Binney Street

BioMed Realty Announces 93,000 Square Foot Lease Expansion And Extension With
                Ironwood Pharmaceuticals At 301 Binney Street

PR Newswire

SAN DIEGO, Oct. 31, 2012

SAN DIEGO, Oct. 31, 2012 /PRNewswire/ --BioMed Realty Trust, Inc. (NYSE: BMR)
today announced the signing of an amendment to the lease with Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) at its 301 Binney Street facility in
Cambridge, Massachusetts. As a result of this lease extension and phased
expansion totaling approximately 93,000 square feet, Ironwood's occupancy in
the five-story, state-of-the-art facility will increase to approximately
303,000 square feet. The term of the lease now extends through January 31,
2018.

Commenting on the lease amendment with Ironwood, Alan D. Gold, Chairman and
Chief Executive Officer of BioMed Realty, said, "We are delighted to expand
and extend our partnership with Ironwood Pharmaceuticals and continue
supporting their ongoing efforts to discover, develop and commercialize
medicines. With this second significant expansion of its footprint at 301
Binney within the past three years, Ironwood continues to manage its growth in
a prudent, measured fashion in the heart of Cambridge, the leading global life
science center."

With this latest lease expansion and extension for Ironwood, BioMed Realty has
leased approximately 600,000 square feet of laboratory and office space in the
Cambridge-Boston market within the past 24 months.

About BioMed Realty Trust

BioMed Realty delivers optimal real estate solutions for biotechnology and
pharmaceutical companies, scientific research institutions, government
agencies and other entities involved in the life science industry. BioMed
Realty owns or has interests in properties comprising approximately 13.1
million rentable square feet. The company's properties are located
predominantly in the major U.S. life science markets of Boston, San Francisco,
San Diego, Maryland, New York/New Jersey, Pennsylvania and Seattle, which have
well-established reputations as centers for scientific research. Additional
information is available at www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These risks
and uncertainties include, without limitation: general risks affecting the
real estate industry (including, without limitation, the inability to enter
into or renew leases, dependence on tenants' financial condition, and
competition from other developers, owners and operators of real estate);
adverse economic or real estate developments in the life science industry or
the company's target markets; risks associated with the availability and terms
of financing, the use of debt to fund acquisitions, developments and other
investments, and the ability to refinance indebtedness as it comes due;
failure to maintain the company's investment grade credit ratings with the
ratings agencies; failure to manage effectively the company's growth and
expansion into new markets, or to complete or integrate acquisitions and
developments successfully; reductions in asset valuations and related
impairment charges; risks and uncertainties affecting property development and
construction; risks associated with downturns in foreign, domestic and local
economies, changes in interest rates and foreign currency exchange rates, and
volatility in the securities markets; ownership of properties outside of the
United States that subject the company to different and potentially greater
risks than those associated with the company's domestic operations; risks
associated with the company's investments in loans, including borrower
defaults and potential principal losses; potential liability for uninsured
losses and environmental contamination; risks associated with the company's
potential failure to qualify as a REIT under the Internal Revenue Code of
1986, as amended, and possible adverse changes in tax and environmental laws;
and risks associated with the company's dependence on key personnel whose
continued service is not guaranteed. For a further list and description of
such risks and uncertainties, see the reports filed by the company with the
Securities and Exchange Commission, including the company's most recent annual
report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.

SOURCE BioMed Realty Trust, Inc.

Website: http://www.biomedrealty.com
Contact: Rick Howe, Senior Director, Corporate Communications,
+1-858-207-5859, richard.howe@biomedrealty.com
 
Press spacebar to pause and continue. Press esc to stop.